Authors

• giovanni marconi
• Gary J. Schiller (ORCID: https://orcid.org/0000-0002-7508-3467)
• Sribalaji Lakshmikanthan
• E C deConinck
• Luca Mazzarella (ORCID: https://orcid.org/0000-0002-4043-3279)
• Ollivier Legrand
• Harry Paul Erba (ORCID: https://orcid.org/0000-0003-1093-2189)
• Yining Du (ORCID: https://orcid.org/0000-0002-1824-392X)
• N. Daver
• H Kantarjian
• J. Potluri
• Maria Benedetta Giannini
• Roland B. Walter
• Andrew A. Lane
• Maisano Valerio
• Delphine Lebon
• David A. Sallman
• Naveen Pemmaraju
• Luca Mazzella
• Roland Walter
• Enrico Derenzini
• Eunice S. Wang
• Matthew L. Ulrickson
• Naval G. Daver
• Andrew Lane
• Pau Montesinos
• Daniel J. DeAngelo

Institutions

• Roswell Park Comprehensive Cancer Center (US)
• Centre National de la Recherche Scientifique (FR)
• City Of Hope National Medical Center (US)
• The University of Texas MD Anderson Cancer Center (US)
• Harvard University (US)
• Inserm (FR)
• University of California, Los Angeles (US)
• University of Milan (IT)
• University of Washington (US)
• Aix-Marseille Université (FR)
• AbbVie (United States) (US)
• Hospital Universitari i Politècnic La Fe (ES)
• Moffitt Cancer Center (US)
• Sorbonne Université (FR)
• Centre Hospitalier Universitaire de Besançon (FR)
• Fred Hutch Cancer Center (US)
• Ospedale "Santa Maria delle Croci" di Ravenna (IT)
• Centre Hospitalier Universitaire Amiens-Picardie (FR)
• Assistance Publique – Hôpitaux de Paris (FR)
• Hôpital Saint-Antoine (FR)
• Dana-Farber Cancer Institute (US)
• Istituto di Ematologia di Bologna (IT)
• Azienda USL di Bologna (IT)
• Duke Medical Center (US)
• Centre de Recherche Saint-Antoine (FR)
• Banner MD Anderson Cancer Center
• Duke Cancer Institute
• Université Marie et Louis Pasteur (FR)
• European Institute of Oncology (IT)
• University of Bologna (IT)

Publication Details

Journal

Journal of Clinical Oncology

Published

2026-02-11

DOI

https://doi.org/10.1200/jco-25-02083

Primary Topic

Cutaneous lymphoproliferative disorders research

Type

article

Field-Weighted Citation Impact

0.00